- Details
- Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA approval for nadofaragene, noting patient interest in new treatment options. Dr. Meeks outlines the challenges with current therapies, including dual chemotherapy and Pembrolizumab, and points to nadofaragene's potential...
|
- Details
- Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer. Dr. Narayan discusses findings from a study utilizing the UroAmp test for assessing urinary minimal residual disease (MRD) in patients treated with nadofaragene. This next-generation sequencing approach reveals the mutation pr...
|
- Details
- Ashish Kamat and Mark Tyson discuss the currently enrolling PIVOT-006 study. Dr. Tyson discusses cretostimogene grenadenorepvec, a conditionally replicating oncolytic adenovirus designed for cancer cell destruction and immunotherapeutic effects. Highlighting four pivotal studies demonstrating the agent's efficacy, especially in BCG unresponsive populations, Dr. Tyson outlines the development of in...
|
- Details
- Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer. Dr. Canter, drawing from his firsthand experience in Phase 1, 2, and 3 trials, highlights the therapy's tolerability and its efficacy, particularly noting its superior administration schedule compared to BCG. With a focus on real-world application, they explore the si...
|
- Details
- Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial's design and objectives, they emphasize its significance in capturing diverse patient experiences and outcomes outside the confines of traditional clinical trials. With nadofaragene firadenovec's unique once-quarterly dosing schedule...
|
- Details
- Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary endpoint...
|
- Details
- Ashish Kamat welcomes David D'Andrea to discuss the eBLOC trial, focusing on en-bloc versus conventional resection of bladder tumors. He highlights the historical context of TURB (Transurethral Resection of Bladder Tumor) and its limited evolution over the years. The eBLOC trial, designed to compare en-bloc and conventional TURB, aimed to improve the quality of resection, crucial for accurate stag...
|
- Details
- Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection in China. Conducted across seven hospitals from November 2022 to June 2023, the study involved 158 patients, with 114 remaining in the final analysis. It demonstrates that BLC, especially with Hexaminolevulinate (HAL) and modern 4K L...
|
- Details
- Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with 7...
|
- Details
- Ashish Kamat welcomes Laura Bukavina to discuss highlights from the SUO 2023 meeting, focusing on bladder cancer research. Dr. Bukavina emphasizes the BOND-003 study on cretostimogene (creto), an adenovirus targeting bladder cancer cells with defective retinoblastoma genes. Creto shows a 75.7% complete response rate, with 74.4% lasting over six months. Another key topic is the ENVISION trial, exam...
|
